Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 27717998.
- Also identified by DOI 10.1007/s00259-016-3536-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Therapy with the alpha-emitter radium-223 chloride (<sup>223</sup>Ra) is an innovative therapeutic option in patients with metastasized, castration-resistant prostate cancer. However, radiotherapy can lead to hematopoietic toxicity. The aim of this study was to determine if <sup>223</sup>Ra therapy induces an impairment of cellular antimicrobial immune responses. In 11 patients receiving <sup>223</sup>Ra treatment, lymphocyte proliferation and the production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) were determined, using lymphocyte transformation testing and ELISpot, respectively. Lymphocyte function after stimulation with mitogens and microbial antigens was assessed prior to therapy and at day 1, 7 and 28 after therapy. Lymphocyte proliferation and the production of interferon-γ and interleukin-10 towards mitogens and antigens remained unchanged after therapy. Consistent with these in vitro data, we did not observe infectious complications after treatment. The results argue against an impairment of lymphocyte function after <sup>223</sup>Ra therapy. Thus, immune responses against pathogens should remain unaffected.
Medical subject headings
- Lymphocyte Activation
- Lymphocytes
- Prostatic Neoplasms, Castration-Resistant
- Radium